Company Filing History:
Years Active: 2017
Title: Innovations by Inventor Hung Keun Lee
Introduction
Hung Keun Lee is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of biomedical research, particularly in the area of treatments for eye-related conditions. His work focuses on innovative solutions that address pressing health issues.
Latest Patents
Hung Keun Lee holds a patent for the "Uses of modified human tumor necrosis factor receptor-1 polypeptide." This invention relates to new applications of modified human tumor necrosis factor receptor-1 (TNFRI) polypeptide, specifically for the prevention and treatment of dry eye syndrome. The modified TNFRI or its fragments exhibit excellent TNFα neutralizing activity, effectively inhibiting TNFα activity on the ocular surface. This suppression of inflammation induction effects is crucial for patients suffering from dry eye syndrome. Therefore, this invention demonstrates remarkable potential in the prevention and treatment of this condition.
Career Highlights
Hung Keun Lee is associated with Hanall Biopharma Co., Ltd., a company dedicated to advancing biopharmaceutical innovations. His work at the company emphasizes the importance of research and development in creating effective medical treatments.
Collaborations
He has collaborated with notable colleagues, including Sung Wuk Kim and Seung Kook Park, to further enhance the impact of his research and innovations.
Conclusion
Hung Keun Lee's contributions to the field of biomedical research, particularly through his patent on modified TNFRI polypeptide, highlight his commitment to improving healthcare solutions. His work is a testament to the importance of innovation in addressing medical challenges.